FDA Rejects Amgen Osteoporosis Drug, Asks For Safety Info
Amgen and Belgian drug manufacturer UCB on Sunday said that the U.S. Food and Drug Administration had rejected its drug for treating osteoporosis in postmenopausal women, citing safety concerns and that...To view the full article, register now.
Already a subscriber? Click here to view full article